1219019-02-9

Usage

Uses

Used in Pharmaceutical Industry:
2-(3,3-difluorocyclobutyl)acetonitrile is used as an intermediate in the synthesis of various pharmaceuticals for its stability and low reactivity, which are desirable properties in the production of drug compounds.
Used in Agrochemical Industry:
Similarly, in the agrochemical industry, 2-(3,3-difluorocyclobutyl)acetonitrile is utilized as an intermediate in the synthesis of agrochemicals, contributing to the development of effective and stable products for agricultural applications.
Used in Material Science:
2-(3,3-difluorocyclobutyl)acetonitrile is used as a building block in the development of new materials, such as polymers and specialty chemicals, due to its potential to enhance the properties of these materials and contribute to innovative product development.

Upstream product

• 681128-40-5 (3,3-difluorocyclobutyl)methyl 4-methylbenzene-1-sulfonate 
• 107496-54-8 3,3-difluorocyclobutanecarboxylic acid 
• 681128-39-2 (3,3-difluorocyclobutyl)methanol 
• 773837-37-9 sodium cyanide 

Downstream Products

• 1373503-48-0 2-(3,3-difluorocyclobutyl)acetic acid 

Relevant academic research and scientific papers

BICYCLIC JAK INHIBITORS AND USES THEREOF

Provided herein are compounds of Formulas (I), (II), (III), and (IV) and subformulas thereof, wherein the variables are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I), (II), (III), or (IV) and methods of using the compounds, e.g., in the treatment of immune disorders, inflammatory disorders, and cancer.

SOLUBLE GUANYLATE CYCLASE ACTIVATORS

A compound of Formula I or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate (" cGMP") and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of Formula I or a pharmaceutically acceptable salt thereof.

SOLUBLE GUANYLATE CYCLASE ACTIVATORS

A compound of Formula I or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate (" cGMP") and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceuticall acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of Formula I or a pharmaceutically acceptable salt thereof.

NOVEL COMPOUNDS

Disclosed are novel retinoid-related orphan receptor gamma (RORγ) modulators and their use in the treatment of diseases mediated by RORγ.

NOVEL COMPOUNDS

The present invention relates to novel retinoid-related orphan receptor gamma (RORγ) modulators and their use in the treatment of diseases mediated by RORγ.

CYCLOALKYL-SUBSTITUTED PYRIMIDINEDIONE COMPOUNDS

The present invention provides novel cycloalkyl-substituted pyrimidine dione compounds that are useful for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic dysfunction. The synthesis and characterization of the compounds is described, as well as methods for treating HCM and other forms of heart disease.

AMIDE COMPOUNDS USEFUL IN THERAPY

A compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, (I) wherein, R1 and R2 each independently represent H, halogen, CF3, C1-3 alkyl or C1-3 alkoxy; R3 represents C1-6 alkyl, C3-6 cycloalkyl, phenyl (optionally substituted by one or more substituents each independently selected from Ra) or Het (optionally substituted by one or more substituents each independently selected from OH, oxo, or C1-4 alkyl); R4 represents H or C1-3 alkyl; R5 represents C1-6 alkyl (optionally substituted by one or more substituents each independently selected from Rb), C3-6 cycloalkyl (optionally substituted by one or more substituents each independently selected from oxo or OH), or Het2 (optionally substituted by one or more substituents each independently selected from Rd); oxygen atom or 1 sulphur atom, or (c) 1 oxygen atom or 1 sulphur atom, (optionally substituted by one or more substituents each independently selected from OH, oxo or C1-4 alkyl); and R6 represents C1-3 alkyl (optionally substituted by one or more substituents each independently selected from Rf), C3-5 cycloalkyl (optionally substituted by one or more halogen), CN or halogen; where Rf represents halogen or phenyl: and compositions, processes for the preparation, and uses thereof, e.g. in the treatment of endometriosis or uterine fibroids.